...大学》2009年硕士论文 te,ORR),4～6个月的疾病进展时间(time to progression,TTP),8～10个月的中位生存期(median survival time,MST),表明对于晚期NSCLC患者的治疗仍十分棘手,如何利用现有医疗资源给予晚期NSCLC患者最优的治疗方..
基于4个网页-相关网页
在治疗结束时，蛋白酶体水平升高患者的中位生存期是30.2个月。蛋白酶体水平恢复正常的患者没有观察到终点事件。
Median survival at the end of treatment was 30.2 months in patients with elevated levels. This point was not reached in patients with normalized levels.
接受氟尿嘧啶联合亚叶酸方案治疗或是吉西他滨方案治疗患者的中位生存期分别为23.0个月及23.6个月。
Median survival for patients treated with fluorouracil plus folinic acid was 23.0 months and for patients treated with gemcitabine was 23.6 months.
血浆中egfr外显子19删除患者的中位生存期要明显好于那些存在L 858r变异患者(32个月相对14个月)。
Median survival time for patients with an EGFR exon 19 deletion in serum was also substantially higher than in those with L858R mutations (32 months vs 14 months).
应用推荐